Abstract:Neurokinin peptides neurokinin‐1 (NK1), neurokinin‐3 (NK3), and related receptors are abundantly distributed in the substantia nigra (SN) and evidenced by their possible roles in the Parkinson’s disease. Differential intervention roles of NK3 on kainic acid (KA)‐induced neuronal injury in the SN of mice were thus in vitro and in vivo studied by Fluoro‐Jade C (FJC) staining, immunohistochemistry to tyrosine hydroxylase (TH) or phospho‐NMDA receptor, and 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay. It revealed that (i) in contrast to protective effect of NK1 agonist septide that reduced FJC‐positive degenerative neurons and lesion volume insulted by KA, NK3 agonist senktide significantly increased FJC‐positive ones and lesion volume, and this effect was sufficiently reversed by NK3 antagonist SB218795; (ii) similarly, senktide reduced TH‐positive neurons and this effect was antagonized by SB218795, but septide increased TH‐positive ones; (iii) mechanistic observation showed differential influences of NK1 and NK3 agonists on phosphorylated‐NMDA receptor subunit 1 (phospho‐NMDAR1) and glial fibrillary acidic protein‐expressing astrocytes, i.e. senktide enhanced of NMDA receptor phosphorylation and astrocyte activity, while septide reduced NMDA receptor phosphorylation and astrocytic response; (iv) cell culture further confirmed the exacerbating effect of NK3 agonist on KA‐induced lesion of nigral cells or dopaminergic neurons, in which administration of senktide alone did not show significant cell toxicity. This study presents new evidence that neurokinin NK3 instead of NK1 synergistically exacerbate excitotoxic neuronal degeneration in the SN in a dose‐dependent manner and possibly through modulation of NMDA receptor phosphorylation and astrocyte activity, suggesting their potential significance in novel pharmaceutical therapy against Parkinson’s disease.

Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.

The P75 Neurotrophin Receptor As a Novel Intermediate in L-dopa-induced Dyskinesia in Experimental Parkinson's Disease.

Kainic Acid-Induced Apoptosis In Rat Striatum Is Associated With Nuclear Factor-Kappa B Activation

p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum.

P75NTR Exacerbates SCI-induced Mitochondrial Damage and Neuronal Apoptosis Depending on NTRK3

P53 Mediates Autophagy Activation and Mitochondria Dysfunction in Kainic Acid-Induced Excitotoxicity in Primary Striatal Neurons

Relationship between expression of p75~(NTR) and cell apoptosis in rat cerebral tissues around hemotomas after intracerebral hemorrhage

The Effects of NF-κB on Parkinson Disease Rat Model Induced by LPS

Update on the Role of P75ntr in Neurological Disorders: A Novel Therapeutic Target.

Update on the role of p75NTR in neurological disorders: A novel therapeutic target

An autophagic mechanism is involved in apoptotic death of rat striatal neurons induced by the non-N-methyl-D-aspartate receptor agonist kainic acid.

Altered Expression of Neurotrophin Receptor P75 NTR in PrP106-126-induced Neurotoxicity of N2a Cells

NF-κB Contributes to 6-Hydroxydopamine-induced Apoptosis of Nigral Dopaminergic Neurons Through P53

Advance in Research on the Apoptosis of Neuronal Cells Mediated by P75ntr

The P35/cdk5 Signaling is Regulated by P75ntr in Neuronal Apoptosis after Intracerebral Hemorrhage.

P75ntr Activation of NF-κB is Involved in PrP106-126-induced Apoptosis in Mouse Neuroblastoma Cells

Characterization of human dopamine responsive protein DRG-1 that binds to p75NTR-associated cell death executor NADE.

Possible Protecting Role of TNF-alpha in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NF kappa B Signaling Pathway

Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tay in Alzheimer patients

Neurokinin‐3 Peptide Instead of Neurokinin‐1 Synergistically Exacerbates Kainic Acid‐inducing Degeneration of Neurons in the Substantia Nigra of Mice

Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.